Archive for July 7, 2014

Clinical evaluation of the Roche Elecsys® CMV IgG Avidity assay

Europ J of Clinic Microb & ID AUG. 2014 V.33  N.8 P.1365-1369

C. Vauloup-Fellous, T. Lazzarotto, M. G. Revello, L. Grangeot-Keros

1. UMR996, Univ Paris-Sud, 92140, Clamart, France

2. AP-HP, Service de Virologie, Hôpital Paul Brousse, Villejuif, France

3. U.O. di Microbiologia, DIMES, Policlinico Universitario St. Orsola-Malpighi, University of Bologna, Bologna, Italy

4. Fondazione IRCCS Policlinico San Matteo, SC Ostetricia e Ginecologia, Pavia, Italy

5. INSERM U764, Université Paris-Sud, AP-HP, Service de Virologie, Hôpital Paul Brousse, Villejuif, France

Congenital cytomegalovirus (CMV) infection has potentially severe consequences in newborns. The testing of pregnant women for CMV-specific antibodies may be useful for the identification of women at risk of transmitting the infection to the fetus.

The determination of CMV IgG avidity helps to establish the timing of infection as IgG avidity matures during the course of infection.

This study examines the performance of the Elecsys® CMV IgG Avidity assay using preselected samples from patients at different phases of CMV infection.

The Elecsys® CMV IgG Avidity assay was tested at three sites using sequential samples from patients with recent primary CMV infection, as well as single samples from patients with recent primary or past CMV infection.

The Elecsys® assay discriminated well between early (low avidity) and late (high avidity) phases of infection in sequential serum samples. Overall, 98.8 % of low-avidity samples corresponded to infection onset <180 days before sampling and 77.8 % of all high-avidity results corresponded to infection onset >90 days before sampling.

The assay’s sensitivity was 90–97 %, with specificity ranging from 89 to 100 %, depending on the consideration of gray-zone avidity values. Single samples from recent primary or past infection showed similar distributions of avidity results.

The Elecsys® CMV IgG Avidity assay results are in agreement with preselected samples from patients with primary or past CMV infection, showing that the test is an adequate predictor of the phase of infection.

abstract

http://link.springer.com/article/10.1007/s10096-014-2080-4?wt_mc=alerts.TOCjournals

PDF

http://download.springer.com/static/pdf/881/art%253A10.1007%252Fs10096-014-2080-4.pdf?auth66=1404904864_7484c24c727d001f225398258776da70&ext=.pdf

 

Advertisements

July 7, 2014 at 9:09 am

Fiebre Chikungunya (CHIKV) – Guía de Manejo Clínico 2014

Fiebre Chikungunya (CHIKV) – Guía de Manejo Clínico 2014

Mrio Salud Rep. Dominicana 55 pags

 

INDICE

Presentación 7

Preguntas claves 11

Metodología para la elaboración de la Guía 12

Alcance y Objetivos de la Guía 14

Epidemiología de la fiebre por chikungunya 17

Definición, manifestaciones y fases clínicas 21

Diagnóstico 26

Tratamiento 29

Informaciones de relevancia para los pacientes 44

Indicadores de calidad 47

Flujograma del proceso de atención 47

Bibliografía  50

PDF

http://www1.paho.org/dor/images/stories/archivos/chikungunya/guia_chikv2.pdf

 

July 7, 2014 at 9:04 am


Calendar

July 2014
M T W T F S S
« Jun   Aug »
 123456
78910111213
14151617181920
21222324252627
28293031  

Posts by Month

Posts by Category